Zacks Investment Research downgraded shares of ARRAY BIOPHARMA (ARRY) from OUTPERFORM to NEUTRAL on August 16, 2012, with a target price of $5.40.
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company's proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on ARRAY BIOPHARMA (ARRY),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment